RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 10.16

Change

-0.16 (-1.55)%

Market Cap

N/A

Volume

2.30K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-05 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

-0.47 (-1.08%)

USD 0.96B
SOXS Direxion Daily Semiconductor B..

-1.59 (-6.39%)

USD 0.61B
PSQ ProShares Short QQQ

-0.51 (-1.31%)

USD 0.50B
SPXU ProShares UltraPro Short S&P50..

-0.75 (-3.14%)

USD 0.48B
SDOW ProShares UltraPro Short Dow30

-1.68 (-3.30%)

USD 0.26B
YANG Direxion Daily FTSE China Bear..

-6.47 (-14.81%)

USD 0.22B
FNGD MicroSectors FANG+ Index -3X I..

-0.37 (-2.46%)

USD 0.14B
RWM ProShares Short Russell2000

-0.20 (-0.99%)

USD 0.14B
SPDN Direxion Daily S&P 500® Bear ..

-0.13 (-1.15%)

USD 0.14B
DUST Direxion Daily Gold Miners Ind..

-3.31 (-6.91%)

USD 0.13B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.62% 22% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.62% 22% F 10% F
Trailing 12 Months  
Capital Gain -4.01% 82% B 27% F
Dividend Return 3.94% 75% C 61% D-
Total Return -0.07% 85% B 27% F
Trailing 5 Years  
Capital Gain -72.10% 69% C- 5% F
Dividend Return 2.50% 68% D+ 6% D-
Total Return -69.61% 69% C- 4% F
Average Annual (5 Year Horizon)  
Capital Gain 64.55% 40% F 95% A
Dividend Return 65.89% 40% F 95% A
Total Return 1.34% 60% D- 32% F
Risk Return Profile  
Volatility (Standard Deviation) 433.47% 62% D 3% F
Risk Adjusted Return 15.20% 49% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.